Rare Tumors (May 2015)

Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma

  • Steven Attia,
  • Scott H. Okuno,
  • Steven I. Robinson,
  • Nicolas P. Webber,
  • Daniel J. Indelicato,
  • Robin L. Jones,
  • Sanjay P. Bagaria,
  • Courtney Sherman,
  • Kevin R. Kozak,
  • Cherise M. Cortese,
  • Thomas MacFarland,
  • Jonathan C. Trent,
  • Robert G. Maki

DOI
https://doi.org/10.4081/rt.2015.5992
Journal volume & issue
Vol. 7, no. 2

Abstract

Read online

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

Keywords